Trial Profile
Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Advanced Parkinson's Disease (PD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Pramipexole (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 28 Mar 2013 New trial record
- 15 Jul 2010 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.